HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
plomestane
selective inhibitor of aromatization in human breast tissue; may provide a mechanism for controlling estrogen responsive processes
Also Known As:
10-PED; 10-propargylandrost-4-ene-3,17-dione; 10-propargylestr-4-ene-3,17-dione; 19-acetylenic androstenedione; MDL 18962; MDL-18,962; Estr-4-ene-3,17-dione, 10-(2-propynyl)-
Networked:
9
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Polycyclic Compounds: 6
Fused-Ring Compounds
Steroids: 70059
Ketosteroids: 23
17-Ketosteroids: 611
Androstenedione: 1298
plomestane: 9
Androstanes: 11
Androstenes: 5
Androstenedione: 1298
plomestane: 9
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones: 80400
Adrenal Cortex Hormones: 62914
17-Ketosteroids: 611
Androstenedione: 1298
plomestane: 9
Gonadal Hormones: 716
Gonadal Steroid Hormones: 7657
Testosterone Congeners: 112
Androstenedione: 1298
plomestane: 9
Organic Chemicals: 133
Amines: 4871
Benzylamines: 10
Pargyline: 171
plomestane: 9
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Benzyl Compounds: 2
Benzylamines: 10
Pargyline: 171
plomestane: 9
Related Diseases
1.
Neoplasms (Cancer)
01/01/1989 - "
SH 489 and MDL 18962 did not affect tumor growth.
"
10/01/1985 - "
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.
"
01/01/1993 - "
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.
"
01/01/1991 - "
Conversely, atamestane, MDL 18962 and oral exemestane did not affect growth of established tumours nor influenced the appearance of new neoplasms.
"
01/01/1990 - "
MDL 18,962, 19-acetylenic androstenedione, is an enzyme-activated inhibitor of estrogen biosynthesis which is in Phase I clinical evaluations as a potential therapeutic agent for estrogen-dependent cancers.
"
2.
Prostatic Neoplasms (Prostate Cancer)
12/01/1989 - "
The effects of 4-hydroxyandrostenedione (4-OHA) and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione and imidazo[1,5-alpha]-3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile), as well as 5 alpha-reductase inhibitors N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide and 4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol were investigated in prostatic tissue from six patients with benign prostatic hypertrophy and seven patients with prostatic cancer, and from normal men at autopsy.
"
12/20/1990 - "
We recently studied the effects of 4-OHA and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione (PED) and imidazo[1,5-alpha]3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile) (CGS 16949A) as well as 5 alpha-reductase inhibitors, N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide (4-MA) and 17 beta-hydroxy-4-aza-4-methyl-19norandrost-5-en-3-one (L651190) in prostatic tissue from 11 patients with prostatic cancer and six patients with benign prostatic hypertrophy (BPH), and from normal men at autopsy.
"
3.
Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/01/1989 - "
The effects of 4-hydroxyandrostenedione (4-OHA) and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione and imidazo[1,5-alpha]-3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile), as well as 5 alpha-reductase inhibitors N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide and 4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol were investigated in prostatic tissue from six patients with benign prostatic hypertrophy and seven patients with prostatic cancer, and from normal men at autopsy.
"
12/20/1990 - "
We recently studied the effects of 4-OHA and other aromatase inhibitors, 10-propargylestr-4-ene-3,17-dione (PED) and imidazo[1,5-alpha]3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile) (CGS 16949A) as well as 5 alpha-reductase inhibitors, N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide (4-MA) and 17 beta-hydroxy-4-aza-4-methyl-19norandrost-5-en-3-one (L651190) in prostatic tissue from 11 patients with prostatic cancer and six patients with benign prostatic hypertrophy (BPH), and from normal men at autopsy.
"
4.
Leydig Cell Tumor
10/01/1985 - "
The murine Leydig cell tumor (M5480A) was assayed for the presence of aromatase activity and for the effects of 10-propargylestr-4-ene-3,17-dione (PED), an aromatase inhibitor, on steroidogenesis.
"
5.
Hepatocellular Carcinoma (Hepatoma)
01/01/1990 - "
The efficacies of 10-propargylestr-4-ene-3,17-dione (PED), 4-hydroxyandrostenedione (4-OHA) and the imidazole broad spectrum antimycotic drugs, econazole, imazalil, miconazole and ketoconazole, to inhibit the steroid aromatase activities of rat Leydig tumor (R2C) cells and human hepatoma (HEPG2) cells have been determined.
"
Related Drugs and Biologics
1.
Aromatase Inhibitors
2.
Estrogens (Estrogen)
3.
formestane
4.
5-alpha Reductase Inhibitors
5.
Enzymes
6.
Aromatase (CYP19)
7.
exemestane (Aromasin)
8.
atamestane
9.
benzonitrile
10.
Fadrozole